Intuitive Surgical slips as antitrust settlement charge overshadows strong Q3 growth
Intuitive Surgical (ISRG) fell 6.2% after reporting Q3 earnings with a $450M antitrust settlement charge, reducing GAAP net income to $523M from $704M YoY. Revenue grew 22% to $3.05B, and procedures increased 15%. The settlement awaits court approval, adding uncertainty.
How this was made

The 30-second read
Why it matters
The settlement charge drives immediate sell‑off, but non‑GAAP earnings and procedure volume growth provide a counterbalance.
Market read
Earnings with a material legal charge create a clear short‑term trading opportunity.
What to watch
Potential upside from continued procedure growth and strong revenue beat may offset the charge over the longer term.
Background
Intuitive Surgical reported Q3 2026 results with 22% revenue growth and a $450M antitrust settlement charge.
Ticker impact
Q3 2026 earnings disclosed a $450M pre‑tax antitrust settlement charge, causing a 6.2% share decline.
downward pressure as investors price in the $450M charge and litigation overhang
Large‑cap earnings with a material one‑time charge typically trigger a sustained sell‑off.
Market effects
Robotic surgery peers may see modest pull‑back as investors reassess litigation exposure.
U.S. healthcare sector could face slight downside pressure.
Limited to medical‑device and tech‑health segments.
Counterpoint
Non‑GAAP earnings remain strong; the charge is one‑time, so the stock could rebound on fundamentals.
Key entities
- companyIntuitive Surgical
U.S. medical‑device maker of da Vinci surgical systems.
